Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.
Management of Advanced Urothelial Carcinoma
Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.
Experts discuss frontline immunotherapy for metastatic urothelial carcinoma when chemotherapy may not be an option.
Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.
Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.
Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.
A brief review of whether FGFR status in metastatic urothelial carcinoma should impact treatment approaches.
Focused discussion on the duration of maintenance avelumab for metastatic urothelial carcinoma and considerations for switching therapy.
Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.
Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.
Expert panelists follow a patient case to discuss locally advanced and metastatic urothelial carcinoma with a focus on frontline and maintenance therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)
5